{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:11:55Z","timestamp":1779894715748,"version":"3.53.1"},"reference-count":89,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T00:00:00Z","timestamp":1291680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>There are a number of options for salvage treatment in children and adolescents with relapsed and refractory classical Hodgkin Lymphoma. These include salvage with standard dose chemotherapy, high dose chemotherapy with autologous stem cell transplant, allogeneic stem cell transplant or other novel approach. Radiotherapy has an important role in the salvage of some patients as part of a combined modality approach. This review outlines these salvage approaches and discusses whether the evidence from paediatric studies justifies a risk\u2010adapted approach to salvage for individual patients or whether all patients should receive consolidation with high dose chemotherapy and autologous stem cell transplantation, which is often described as standard salvage management in adults. The important prognostic factors and how these may be used to allocate patients to standard <jats:italic>versus<\/jats:italic> high dose chemotherapy regimens are discussed. The role of allogeneic transplantation, novel agents and late effects will also be discussed.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08455.x","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T09:59:15Z","timestamp":1291715955000},"page":"249-260","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents"],"prefix":"10.1111","volume":"152","author":[{"given":"Stephen","family":"Daw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,7]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.197"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026454831340"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.825"},{"key":"e_1_2_16_5_1","first-page":"73","article-title":"The incidence and treatment of the first relapse in children with Hodgkin\u2019s disease","volume":"4","author":"Balwierz W.","year":"2000","journal-title":"Medycyna Wieku Rozwojowego"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2002.t01-1-01007.x"},{"key":"e_1_2_16_7_1","article-title":"Outcome of second line therapy for pediatric patients with Hodgkin lymphoma who relapse following ABVD based therapy","volume":"114","author":"Belgaumi A.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/088800100276415"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.528"},{"key":"e_1_2_16_10_1","first-page":"51","article-title":"High\u2010dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin\u2019s disease","volume":"64","author":"Bonfante V.","year":"2001","journal-title":"European Journal of Haematology"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.11.354"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06998.x"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700838"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.05.006"},{"issue":"11","key":"e_1_2_16_15_1","doi-asserted-by":"crossref","first-page":"A\u20101896","DOI":"10.1182\/blood.V110.11.1896.1896","article-title":"Clinical outcomes of patients with recurrent\/refractory Hodgkin disease receiving cyclosporine, interferon\u2010V and interleukin\u20102 immunotherapy to induce autoreactivity after autologous stem cell transplantation with BEAM: a COG study","volume":"110","author":"Chen A.R.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_16_16_1","first-page":"1878","article-title":"The impact of disease status at transplant and time to first relapse on outcome in children and adolescents with Hodgkin\u2019s lymphoma undergoing autologous stem cell transplantation","volume":"104","author":"Claviez A.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_16_17_1","first-page":"3061","article-title":"The impact of allogeneic hematopoietic stem cell transplantation in children and adolescents with recurring Hodgkin\u2019s lymphoma: an EBMT study on 151 patients","volume":"110","author":"Claviez A.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.278"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-189399"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3778"},{"key":"e_1_2_16_21_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.1987.5.5.742","article-title":"Combined modality treatment with low\u2010dose radiation and MOPP chemotherapy for children with Hodgkin\u2019s disease","volume":"5","author":"Donaldson S.S.","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.4772"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39372"},{"key":"e_1_2_16_24_1","first-page":"99","article-title":"Risk adapted combined modality treatment in children with Hodgkin\u2019s disease","volume":"20","author":"El\u2010 Badawy S.","year":"2008","journal-title":"Journal of the Egyptian National Cancer Institute"},{"key":"e_1_2_16_25_1","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood.V112.11.2595.2595","article-title":"A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma (cHL): preliminary results [abstract]","volume":"112","author":"Fehniger T.A.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11215699"},{"key":"e_1_2_16_27_1","first-page":"843","article-title":"Safety and efficacy of CBV followed by autologous PBSC transplant in children with lymphoma after failed induction or first relapse\u2014a Children\u2019s Oncology Group Study","volume":"46","author":"Harris R.L.","year":"2006","journal-title":"Pediatric Blood and Cancer"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.393"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2007.02.009"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2160"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.897"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.426"},{"key":"e_1_2_16_33_1","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V110.11.2555.2555","article-title":"mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001) [abstract]","volume":"110","author":"Johnston P.B.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.221"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi003"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.022"},{"key":"e_1_2_16_37_1","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V112.11.3052.3052","article-title":"Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract]","volume":"112","author":"Kuruvilla J.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.13.971"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90460-D"},{"key":"e_1_2_16_40_1","first-page":"2635","article-title":"Phase II study of SGN\u201030 (anti\u2010CD30 monoclonal antibody in patients with refractory or recurrent Hodgkin\u2019s disease","volume":"104","author":"Leonard J.P.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.121"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.210"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02714.x"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3163"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1261"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3173"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.616"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2003.04828.x"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08037.x"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00180-7"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66659-7"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703891"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00277-5"},{"key":"e_1_2_16_55_1","first-page":"2088","article-title":"High dose therapy (HDCT) and autologous haematopoietic stem cell transplantation (aSCT) in paediatric patients with recurrent or refractory Hodgkin\u2019s disease (HD): results and outcome","volume":"106","author":"Prete A.","year":"2005","journal-title":"Blood (ASH Annual meeting abstracts)"},{"key":"e_1_2_16_56_1","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/jco.2007.25.18_suppl.3500","article-title":"Phase I study oral LBH589, a novel deacetylase (DAC) inhibitor advanced solid tumors and non\u2010Hodgkin\u2019s lymphoma abstract]","volume":"25","author":"Prince H.M.","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg710"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13441"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500178167"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10661"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(96)80030-8"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1026870"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3736"},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.930"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.098"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184143"},{"key":"e_1_2_16_68_1","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN)(2004)Long term follow up of survivors of childhood cancer.A national clinical guideline. Guideline 76.http:\/\/www.sign.ac.uk\/pdf\/sign76.pdf."},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903580410"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2622"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70724-0"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.124"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3842"},{"key":"e_1_2_16_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200411000-00010"},{"key":"e_1_2_16_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2415"},{"key":"e_1_2_16_76_1","first-page":"290","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"23","author":"Travis L.B.","year":"2003","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_16_77_1","first-page":"97","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"5","author":"Travis L.B.","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"key":"e_1_2_16_78_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00561.x"},{"key":"e_1_2_16_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930915)72:6<2049::AID-CNCR2820720642>3.0.CO;2-V"},{"key":"e_1_2_16_80_1","first-page":"5,434","article-title":"Childhood Hodgkin\u2019s disease: results of the Italian multicentric study AIEOP\u2010MH\u201989\u2010CNR","volume":"29","author":"Vecchi V.","year":"1997","journal-title":"Medical Paediatric Oncology"},{"key":"e_1_2_16_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702094"},{"key":"e_1_2_16_82_1","doi-asserted-by":"crossref","unstructured":"Wallace W.H.&Barr R.D.(2010)Fertility preservation for girls and young women with cancer: what are the remaining challenges?Human Reproduction Update 16(6) 614\u2013616.","DOI":"10.1093\/humupd\/dmq038"},{"key":"e_1_2_16_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70092-9"},{"key":"e_1_2_16_84_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood.V110.11.215.215","article-title":"Rituximab\u2003+\u2003ABVD improves event\u2010free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2\u20133 cycles of therapy [abstract]","volume":"110","author":"Wedgwood A.R.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_16_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2243"},{"key":"e_1_2_16_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20563"},{"key":"e_1_2_16_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11511"},{"key":"e_1_2_16_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3731"},{"key":"e_1_2_16_89_1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.V112.11.1006.1006","article-title":"Multiple complete responses in a phase 1 dose\u2010escalation study of the antibody\u2010drug conjugate SGN\u201035 in patients with relapsed or refractory CD30\u2010positive lymphomas [abstract]","volume":"112","author":"Younes A.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_16_90_1","first-page":"34","article-title":"Phase II study of oral panobinostat in patients with relapsed\/refractory Hodgkin lymphoma (HL) after high\u2010dose chemotherapy with autologous stem cell transplant (ASCT) [abstract]","volume":"94","author":"Younes A.","year":"2009","journal-title":"Haematologica"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08455.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08455.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:41:01Z","timestamp":1697427661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08455.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,7]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08455.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08455.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,7]]},"assertion":[{"value":"2010-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}